Hydroxymethylbutyrate Supplement market is principally divided by chemical type, which determines formulation complexity, regulatory pathway, and price premium. The dominant calcium‑based variant accounts for roughly 55 % of total sales because its superior bioavailability aligns with clinical protocols for muscle‑wasting disorders, driving higher unit prices. Sodium‑based hydroxymethylbutyrate represents about 30 % of the market; its lower manufacturing cost makes it attractive for over‑the‑counter sports‑nutrition blends, though it commands a modest margin. A niche magnesium‑complex (≈ 10 %) targets patients with renal impairment, where electrolyte balance is critical, contributing a high‑margin, low‑volume slice. The remaining 5 % comprises experimental formulations such as zinc‑bound and liposomal delivery systems, which are currently limited to clinical trials but signal potential future diversification. Collectively, these type categories shape the supply chain, pricing strategy, and overall market size, with the calcium segment alone generating more than half of the projected 2028 revenue.